

**P2RX5 Antibody (C-term) Blocking peptide**  
**Synthetic peptide**  
**Catalog # BP14059b****Specification**

---

**P2RX5 Antibody (C-term) Blocking peptide - Product Information**Primary Accession [Q93086](#)**P2RX5 Antibody (C-term) Blocking peptide - Additional Information****Gene ID** 5026**Other Names**

P2X purinoceptor 5, P2X5, ATP receptor, Purinergic receptor, P2RX5, P2X5

**Target/Specificity**

The synthetic peptide sequence used to generate the antibody AP14059b was selected from the C-term region of P2RX5. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

**Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**P2RX5 Antibody (C-term) Blocking peptide - Protein Information****Name** P2RX5**Synonyms** P2X5**Function**

Receptor for ATP that acts as a ligand-gated ion channel.

**Cellular Location**

Membrane; Multi-pass membrane protein.

**Tissue Location**

Expressed at high levels in brain and immune system

**P2RX5 Antibody (C-term) Blocking peptide - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

#### **P2RX5 Antibody (C-term) Blocking peptide - Images**

#### **P2RX5 Antibody (C-term) Blocking peptide - Background**

The product of this gene belongs to the family of purinoceptors for ATP. This receptor functions as a ligand-gated ion channel. Several characteristic motifs of ATP-gated channels are present in its primary structure, but, unlike other members of the purinoceptors family, this receptor has only a single transmembrane domain. Three transcript variants encoding distinct isoforms have been identified for this gene.

#### **P2RX5 Antibody (C-term) Blocking peptide - References**

Kotnis, S., et al. Mol. Pharmacol. 77(6):953-960(2010) Overes, I.M., et al. Cancer Immunol. Immunother. 58(3):429-439(2009) Dubyak, G.R. Mol. Pharmacol. 72(6):1402-1405(2007) Lamesch, P., et al. Genomics 89(3):307-315(2007) Duckwitz, W., et al. J. Biol. Chem. 281(51):39561-39572(2006)